Biglycan Interacts with Type I Insulin-like Receptor (IGF-IR) Signaling Pathway to Regulate Osteosarcoma Cell Growth and Response to Chemotherapy

SIMPLE SUMMARY: Osteosarcoma (OS) is an aggressive, primary bone cancer. OS cells produce altered osteoid whose components participate in signaling correlated to the development of this cancer. Biglycan (BGN), a proteoglycan, is correlated to aggressive OS type and resistance to chemotherapy. A cons...

Descripción completa

Detalles Bibliográficos
Autores principales: Giatagana, Eirini-Maria, Berdiaki, Aikaterini, Gaardløs, Margrethe, Samsonov, Sergey A., Tzanakakis, George N., Nikitovic, Dragana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909324/
https://www.ncbi.nlm.nih.gov/pubmed/35267503
http://dx.doi.org/10.3390/cancers14051196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909324/
https://www.ncbi.nlm.nih.gov/pubmed/35267503
http://dx.doi.org/10.3390/cancers14051196

Ejemplares similares